logologo

close

COPYRIGHT 2020 POSVAX CO. LTD. ALL RIGHTS RESERVED.

r&d

Prophylactic Vaccines

Alzheimer’s Disease Vaccines

oldman

Alzheimer’s disease is a progressive dementia showing changes in brain similar to aging occurring to the elderly over 65. Almost 60 % of the Alzheimer’s disease is a progressive dementia and it will degrade overall quality of life, and even lead to death

Expected number of Alzheimer’s Disease patients
  • World
  • Rep.
    Korea
  • In 2018
  • In 2030
  • In 2018
  • In 2030
  • 50,000,000
  • 75,000,000
  • 700,000
  • 1,500,000

자료)국제알츠하이머협회(ADI·Alzheimer’s Disease International)와
한국중앙치매센터 '대한민국 치매현황 2018”

Alzheimer’s Disease Vaccines Highlights

POSVAX
ALZHEIMER'S
DISEASE
VACCINES

FEATURES
  • VLP-based prophylactic
    vaccines
  • Excellent tactics to block
    β-amyloid accumulation
STATE OF
DEVELOPMENT
  • Exploring excellent
    VLP vaccine antigens
EFFICACY
  • Decrease alzheimer’s
    disease rate
  • Decrease medical cost
    burdens through
    preemptive prevention
FUTURE
MARKET
  • High expectation of prophylactic
    vaccines due to difficult
    developing treatment drugs
  • Increasing prophylactic vaccine
    market due to entry to the
    rapid aging society